Recent drug development and treatments for fungal infections

Braz J Microbiol. 2023 Sep;54(3):1695-1716. doi: 10.1007/s42770-023-00999-z. Epub 2023 May 23.

Abstract

Fungal infections are now becoming a hazard to individuals which has paved the way for research to expand the therapeutic options available. Recent advances in drug design and compound screening have also increased the pace of the development of antifungal drugs. Although several novel potential molecules are reported, those discoveries have yet to be translated from bench to bedside. Polyenes, azoles, echinocandins, and flucytosine are among the few antifungal agents that are available for the treatment of fungal infections, but such conventional therapies show certain limitations like toxicity, drug interactions, and the development of resistance which limits the utility of existing antifungals, contributing to significant mortality and morbidity. This review article focuses on the existing therapies, the challenges associated with them, and the development of new therapies, including the ongoing and recent clinical trials, for the treatment of fungal infections. Advancements in antifungal treatment: a graphical overview of drug development, adverse effects, and future prospects.

Keywords: Anti-fungals; Clinical trials; Drug development; Fungicides; Pharmacology.

Publication types

  • Review

MeSH terms

  • Antifungal Agents* / pharmacology
  • Antifungal Agents* / therapeutic use
  • Azoles / pharmacology
  • Azoles / therapeutic use
  • Drug Development
  • Drug Resistance, Fungal
  • Echinocandins
  • Humans
  • Mycoses* / drug therapy
  • Mycoses* / microbiology

Substances

  • Antifungal Agents
  • Echinocandins
  • Azoles